About the Authors
- Niklas Mattsson
-
* E-mail: niklas.mattsson@neuro.gu.se (NM); erik.portelius@neuro.gu.se (EP)
Affiliation Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden
- Lawrence Rajendran
-
Affiliation Systems and Cell Biology of Neurodegeneration, Division of Psychiatry Research, University of Zurich, Zurich, Switzerland
- Henrik Zetterberg
-
Affiliation Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden
- Mikael Gustavsson
-
Affiliation Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden
- Ulf Andreasson
-
Affiliation Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden
- Maria Olsson
-
Affiliation Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden
- Gunnar Brinkmalm
-
Affiliation Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden
- Johan Lundkvist
-
Affiliation Innovative Medicines, Central Nervous System and Pain iMed, Department of Neuroscience, AstraZeneca R&D, Södertälje, Sweden
- Laura H. Jacobson
-
Affiliation Neuroscience Discovery, Novartis Institutes for BioMedical Research, Basel, Switzerland
- Ludovic Perrot
-
Affiliation Neuroscience Discovery, Novartis Institutes for BioMedical Research, Basel, Switzerland
- Ulf Neumann
-
Affiliation Neuroscience Discovery, Novartis Institutes for BioMedical Research, Basel, Switzerland
- Herman Borghys
-
Affiliation Neuroscience Therapeutic Area, Janssen Research and Development, Beerse, Belgium
- Marc Mercken
-
Affiliation Neuroscience Therapeutic Area, Janssen Research and Development, Beerse, Belgium
- Deborah Dhuyvetter
-
Affiliation Neuroscience Therapeutic Area, Janssen Research and Development, Beerse, Belgium
- Fredrik Jeppsson
-
Affiliation Innovative Medicines, Central Nervous System and Pain iMed, Department of Neuroscience, AstraZeneca R&D, Södertälje, Sweden
- Kaj Blennow
-
Affiliation Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden
- Erik Portelius
-
* E-mail: niklas.mattsson@neuro.gu.se (NM); erik.portelius@neuro.gu.se (EP)
Affiliation Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden
Competing Interests
The authors have read the journal's policy and have the following conflicts: JL and FP are employed by Astra Zeneca. LHJ, LP and UN are employed by Novartis. HB, MM and DD are employed by Janssen. Astra Zeneca patent: * AZ-20 International application WO2010/056196. Novartis patents: * NB-B4 WO2010/003976 A1, 14. Jan 2010 * NB-C8 WO2011/009943 A1, 27. Jan 2011 Janssen patents: * (Applied for) Beauchamp, Jeremy; Benardeau, Agnes; Hilpert, Hans; Migliorini, Cristiano; Riboulet, William; Wang, Haiyan. 2-Aminodihydro[1,3]thiazines as BACE 2 inhibitors and their preparation and use in the treatment of diabetes. PCT Int. Appl. (2011), 64pp. CODEN: PIXXD2 WO 2011029803 A1 20110317 CAN 154:361040 AN 2011:326345 CAPLUS * (Applied for) Kobayashi, Naotake; Ueda, Kazuo; Itoh, Naohiro; Suzuki, Shinji; Sakaguchi, Gaku; Kato, Akira; Yukimasa, Akira; Hori, Akihiro; Kooriyama, Yuji; Haraguchi, Hidekazu; Yasui, Ken; Kanda, Yasuhiko. Preparation of 2-amino-4-phenyl-4,5-dihydro-5H-1,3-thiazine derivatives and related compounds for treatment of Alzheimer's disease. PCT Int. Appl. (2008), 354pp. CODEN: PIXXD2 WO 2008133273 A1 20081106 CAN 149:534229 AN 2008:1339943 CAPLUS * (Granted in South Korea) Kobayashi, Naotake; Ueda, Kazuo; Itoh, Naohiro; Suzuki, Shinji; Sakaguchi, Gaku; Kato, Akira; Yukimasa, Akira; Hori, Akihiro; Koriyama, Yuji; Haraguchi, Hidekazu; Yasui, Ken; Kanda, Yasuhiko. Preparation of 2-aminodihydrothiazine derivatives as beta-secretase inhibitors. PCT Int. Appl. (2007), 330pp. CODEN: PIXXD2 WO 2007049532 A1 20070503 CAN 146:482079 AN 2007:485607 CAPLUS This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials, as detailed online in the guide for authors.
Author Contributions
Conceived and designed the experiments: EP NM KB HZ JL FJ LR LHJ LP UN HB MM DD. Performed the experiments: MO MG JL FJ LR LHJ LP UN HB MM DD GB EP. Analyzed the data: EP NM UA. Contributed reagents/materials/analysis tools: JL FJ LR LHJ LP UN HB MM DD UA. Wrote the paper: EP NM.